AI Article Synopsis
- Biosimilars are replicas of original biopharmaceuticals and hold a major share in this industry, particularly exemplified by Adalimumab (Humira), a monoclonal antibody that effectively blocks TNF-α with low immunogenicity.
- To address the challenges of cost-effective monoclonal antibody development, researchers created a stable CHO-K1 cell line to produce a new biosimilar called H9P2S against TNF-α.
- Functional assays demonstrated that H9P2S exhibits comparable TNF-α binding and neutralizing properties to Adalimumab, suggesting it is a viable option for biosimilar drug development.
Article Abstract
Unlabelled: Biosimilars, which are replicas of innovator pharmaceuticals, constitute the most significant share of biopharmaceutical products. These products are associated with structural and manufacturing complexities and are hence considered as similar to innovator drugs. Adalimumab is a monoclonal antibody that has been approved by the US FDA for blocking TNF-α. Adalimumab, also known as Humira, is preferred over other anti-TNF-α mAbs because of its lower immunogenicity and enhanced clinical efficacy. As cost-effective mAb development is still a challenging area, we developed an in-house stable CHO-K1 cell line for the production of recombinant monoclonal mAb against TNF-α. This clone yielded H9P2S, as a biosimilar against TNF-α, for which several functional assays were conducted to prove its biosimilarity to Adalimumab. Two batches of H9P2S and their subsequent dilutions were compared with Adalimumab. H9P2S and Adalimumab showed highly similar TNF-α binding and neutralizing activities, confirming the suitability of our clone for yielding biosimilar drugs.
Supplementary Information: The online version contains supplementary material available at 10.1007/s13205-022-03384-z.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547763 | PMC |
| http://dx.doi.org/10.1007/s13205-022-03384-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!